Journal of Jilin University(Medicine Edition) ›› 2023, Vol. 49 ›› Issue (1): 122-130.doi: 10.13481/j.1671-587X.20230116
• Research in basic medicine • Previous Articles Next Articles
Junyi JIN,Mu LI,Yaoyuan HU,Yihui WANG(
)
Received:2022-03-21
Online:2023-01-28
Published:2023-02-03
Contact:
Yihui WANG
E-mail:wangyihui@sj-hospital.org
CLC Number:
Junyi JIN,Mu LI,Yaoyuan HU,Yihui WANG. Targeting relationship between miR-150-5p and NCAPG and its inhibitory effect on hepatocellular carcinoma Huh7 cells[J].Journal of Jilin University(Medicine Edition), 2023, 49(1): 122-130.
Tab. 1
Primer sequences of RT-qPCR"
| Gene | Primer sequence |
|---|---|
| miR-150-5p | Forward: 5'-TCGGCGTCTCCCAACCCTTGTAC-3' Reverse: 5'-GTCGTATCCAGTGCAGGGTCCGAGGT-3' |
| NCAPG | Forward: 5'-ATTGCTTTGTATTGGTGTGCCCTTTG-3' Reverse: 5'-ACAACTGGAATGCTCTGGATGTAACTC-3' |
| GAPDH | Forward: 5'-CGGAGTCAACGGATTTGGTCGTAT-3' Reverse: 5'-AGCCTTCTCCATGGTGGTGAAGAC-3' |
| U6 | Forward: 5'-TGCGGGTGCTCGCTTCGGCAGC-3' Reverse: 5'-CCAGTGCAGGGTCCGAGGT-3' |
Tab.3
Tumor volumes of nude mice in various groups at different time (n=5,x±s, V/mm3)"
| Group | Tumor volume | ||||||
|---|---|---|---|---|---|---|---|
| (t/d) 3 | 6 | 9 | 12 | 15 | 18 | 21 | |
| AgomiR-NC | 4.18±0.87 | 8.24±1.48 | 55.35±8.77 | 98.72±21.35 | 174.25±42.88 | 382.54±87.66 | 689.09±211.94 |
| AgomiR-150-5p | 3.44±0.66 | 5.86±1.08 | 15.82±3.42* | 27.52±5.77* | 35.47±4.82* | 56.45±9.21* | 123.24±19.96* |
| AgomiR-150-5p+ovNC | 3.12±0.48 | 5.77±0.75 | 14.33±2.95 | 21.85±4.32 | 32.35±5.89 | 51.08±8.77 | 116.04±19.04 |
| AgomiR-150-5p+ovNCAPG | 4.56±0.74 | 7.52±0.98 | 28.52±1.77△ | 42.74±8.77△ | 68.75±18.72△ | 108.95±30.27△ | 229.86±81.88△ |
| 1 | SIEGEL R L, MILLER K D, FUCHS H E, et al. Cancer statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1): 7-33. |
| 2 | LIU W W, LIANG B, LIU H L, et al. Overexpression of non‑SMC condensin Ⅰ complex subunit G serves as a promising prognostic marker and therapeutic target for hepatocellular carcinoma[J]. Int J Mol Med, 2017, 40(3): 731-738. |
| 3 | LIU K K, LI Y M, YU B, et al. Silencing non-SMC chromosome-associated polypeptide G inhibits proliferation and induces apoptosis in hepatocellular carcinoma cells[J]. Can J Physiol Pharmacol, 2018, 96(12): 1246-1254. |
| 4 | GONG C W, AI J Y, FAN Y, et al. NCAPG promotes the proliferation of hepatocellular carcinoma through PI3K/AKT signaling[J]. Onco Targets Ther, 2019, 12: 8537-8552. |
| 5 | OURA K, MORISHITA A, MASAKI T. Molecular and functional roles of microRNAs in the progression of hepatocellular carcinoma-A review[J]. Int J Mol Sci, 2020, 21(21): 8362. |
| 6 | CUI X, JIANG X Y, WEI C S, et al. Astragaloside Ⅳ suppresses development of hepatocellular carcinoma by regulating miR-150-5p/β-catenin axis[J]. Environ Toxicol Pharmacol, 2020, 78: 103397. |
| 7 | BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. |
| 8 | KULIK L, EL-SERAG H B. Epidemiology and management of hepatocellular carcinoma[J]. Gastroenterology, 2019, 156(2): 477-491. |
| 9 | SCHLABE S, ROCKSTROH J K. Advances in the treatment of HIV/HCV coinfection in adults[J]. Expert Opin Pharmacother, 2018, 19(1): 49-64. |
| 10 | HUO T I, HSU C Y, LIU P H. Magic mirror on the wall: which is the best biomarker for hepatocellular carcinoma?[J]. Hepatology, 2018, 67(6): 2482-2483. |
| 11 | HARTKE J, JOHNSON M, GHABRIL M. The diagnosis and treatment of hepatocellular carcinoma[J]. Semin Diagn Pathol, 2017, 34(2): 153-159. |
| 12 | SUN J Y, YIN T L, ZHANG X Y, et al. Therapeutic advances for patients with intermediate hepatocellular carcinoma[J]. J Cell Physiol, 2019, 234(8): 12116-12121. |
| 13 | YERUKALA SATHIPATI S, HO S Y. Novel miRNA signature for predicting the stage of hepatocellular carcinoma[J].Sci Rep,2020,10(1):14452. |
| 14 | MOHAMED A A, ALI-ELDIN Z A, ELBEDEWY T A,et al. MicroRNAs and clinical implications in hepatocellular carcinoma[J]. World J Hepatol, 2017, 9(23): 1001-1007. |
| 15 | CHEN F, LI X F, FU D S, et al. Clinical potential of miRNA-221 as a novel prognostic biomarker for hepatocellular carcinoma[J]. Cancer Biomark, 2017, 18(2): 209-214. |
| 16 | HUNG J H, LI C H, YEH C H, et al. microRNA-224 down-regulates glycine N-methyltransferase gene expression in Hepatocellular Carcinoma[J]. Sci Rep, 2018, 8(1): 12284. |
| 17 | JIANG C, HE Z L, HU X H, et al. MiRNA-15a-3p inhibits the metastasis of hepatocellular carcinoma by interacting with HMOX1[J]. Eur Rev Med Pharmacol Sci, 2020, 24(24): 12694-12700. |
| 18 | YU W S, WANG Z G, GUO R P, et al. Hepatocellular carcinoma progression is protected by miRNA-34c-5p by regulating FAM83A[J]. Eur Rev Med Pharmacol Sci, 2020, 24(11): 6046-6054. |
| 19 | CHEN X X, XU X N, PAN B, et al. miR-150-5p suppresses tumor progression by targeting VEGFA in colorectal cancer[J].Aging (Albany NY),2018,10(11): 3421-3437. |
| 20 | LU W, ZHANG H H, NIU Y Q, et al. Long non-coding RNA linc00673 regulated non-small cell lung cancer proliferation, migration, invasion and epithelial mesenchymal transition by sponging miR-150-5p[J]. Mol Cancer, 2017, 16(1): 118. |
| 21 | JIANG L L, REN L L, CHEN H, et al. NCAPG confers trastuzumab resistance via activating SRC/STAT3 signaling pathway in HER2-positive breast cancer[J]. Cell Death Dis, 2020, 11(7): 547. |
| 22 | WU Y, LIN Y, PAN J F, et al. NCAPG promotes the progression of lung adenocarcinoma via the TGF-β signaling pathway[J]. Cancer Cell Int,2021,21(1): 443. |
| 23 | WANG Y, GAO B, TAN P Y, et al. Genome-wide CRISPR knockout screens identify NCAPG as an essential oncogene for hepatocellular carcinoma tumor growth[J]. FASEB J, 2019, 33(8): 8759-8770. |
| 24 | GUO Z Y, ZHU Z T. NCAPG is a prognostic biomarker associated with vascular invasion in hepatocellular carcinoma[J]. Eur Rev Med Pharmacol Sci, 2021, 25(23): 7238-7251. |
| 25 | AI J Y, GONG C W, WU J J, et al. microRNA‑181c suppresses growth and metastasis of hepatocellular carcinoma by modulating NCAPG[J]. Cancer Manag Res, 2019, 11: 3455-3467. |